Transcription
Biocon Limited20th KM, Hosur RoadElectronic CityBangalore 560 100, IndiaT 91 80 2808 2808F 91 80 2852 3423CIN : L24234KA1978PLC003417www.biocon.comNovember 19, 2021To,The ManagerBSE LimitedDepartment of Corporate ServicesPhiroze Jeejeebhoy Towers,Dalal Street, Mumbai – 400 001Scrip Code – 532523To,The ManagerNational Stock Exchange of India LimitedCorporate Communication DepartmentExchange Plaza, Bandra Kurla ComplexMumbai – 400 050Scrip Symbol - BioconDear Sir/Madam,Subject: Corrigendum to our press release titled “Biocon Biologics and Viatris Announce Insulin Glargine(insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club.”With reference to our recent intimation titled “Biocon Biologics and Viatris Announce Insulin Glargine(insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club”, wehereby request you to read the word “Press Release” as “Company Statement”.Please find attached the Company Statement for your reference.The above information will also be available on the website of the Company at www.biocon.com.Kindly take the same on record and acknowledge.Thanking You,Yours faithfully,For Biocon LimitedMayank VermaCompany Secretary and Compliance OfficerEnclosed: Press Release
INTIMATION TO STOCK EXCHANGEBiocon Biologics and Viatris Announce Insulin Glargine (insulinglargine-yfgn) Injection Will Be Offered Through theWalgreens Prescription Savings ClubMembers can save up to 80 percent off the cash price of comparable long-actinginsulins purchased at WalgreensBengaluru, Karnataka, India – November 19, 2021Biocon Biologics Ltd., a subsidiary of Biocon Ltd., and Viatris Inc. are proud to confirmthat Insulin Glargine (insulin glargine-yfgn) injection will be offered through theWalgreens Prescription Savings Club, saving members up to 80 percent off the cash priceof comparable long-acting insulins purchased at Walgreens.This decision by Walgreens follows the launch of Insulin Glargine (insulin glargine-yfgn)announced on November 16. Biocon Biologics and Viatris co-developed the product, andtogether the companies are committed to improving patients' access to sustainable,quality and more affordable healthcare.Biocon Biologics and Viatris are together committed to ensuring that the interchangeablebiosimilar insulin glargine can reach as many patients as possible regardless of financialcircumstances, insurance or channel. The collaboration with Walgreens underscores ourefforts to improve outcomes and access for patients by meeting the needs of cash-payingpatients and partnering with key stakeholders across the country to lower out-of-pocketcosts for insulin users.Indications and Important Safety InformationSemglee is a long-acting human insulin analog indicated to improve glycemic control in adultsand pediatric patients with Type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.It is not recommended for the treatment of diabetic ketoacidosis. Do not use during episodes ofhypoglycemia or if hypersensitive to insulin glargine or its excipients. Patients should beinstructed to never share the prefilled pen even if the needle is changed. Changes to a patient’sinsulin regimen should be done under close medical supervision with increased frequency ofblood glucose monitoring as hyper- or hypoglycemia may occur. Hypoglycemia is the mostcommon adverse reaction with insulin, including Semglee and it may be life-threatening. Increase1
frequency of glucose monitoring when there are changes to: insulin dosage, coadministeredglucose lowering medications, meal pattern, physical activity; and in patients with renal orhepatic impairment and hypoglycemia unawareness. Patients and caregivers must be educatedto recognize and manage hypoglycemia. Medication errors can result from accidental mix-upsamong insulin products. Instruct patients to always check the insulin label before injection.Severe, life-threatening generalized allergy, including anaphylaxis can occur with insulinproducts, including Semglee. If hypersensitivity reaction occurs, discontinue Semglee and treatper standard of care and monitor until symptoms and signs resolve. Monitor potassium levelsfor hypokalemia and treat if indicated. Fluid retention and heart failure have been reported withconcomitant use of thiazolidinediones (TZD). Observe for signs and symptoms of heart failure;consider dosage reduction or discontinuation of TZD if heart failure occurs.About Biocon Biologics LimitedBiocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilarsorganization. It is leveraging cutting-edge science, innovative tech platforms and advancedresearch & development capabilities to lower treatment costs while improving healthcareoutcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology,immunology, and other non- communicable diseases. Five molecules from Biocon Biologics’portfolio have been taken from lab to market in developed markets like United States, EU,Australia, Canada and Japan. With a team of 4,800 people, Biocon Biologics is committed totransforming healthcare and transforming lives by enabling affordable access to millions ofpatients’ worldwide. www.biocon.com/businesses/biosimilars/Follow-us on Twitter: @BioconBiologicsAbout Biocon LimitedBiocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id:INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhanceaffordable access to complex therapies for chronic conditions like diabetes, cancer andautoimmune. It has developed and commercialized novel biologics, biosimilars, and complexsmall molecule APIs in India and several key global markets as well as Generic Formulations inthe US and Europe. It also has a pipeline of promising novel assets in immunotherapy underdevelopment. Website: www.biocon.com; Follow-us on Twitter: @bioconlimitedAbout ViatrisViatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwideto live healthier at every stage of life. We provide access to medicines, advance sustainableoperations, develop innovative solutions and leverage our collective expertise to connect morepeople to more products and services through our one-of-a-kind Global Healthcare Gateway .Formed in November 2020, Viatris brings together scientific, manufacturing and distributionexpertise with proven regulatory, medical and commercial capabilities to deliver high-qualitymedicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises2
more than 1,400 approved molecules across a wide range of therapeutic areas, spanning bothnon-communicable and infectious diseases, including globally recognized brands, complexgeneric and branded medicines, a growing portfolio of biosimilars and a variety of over-thecounter consumer products. With a global workforce of approximately 38,000, Viatris isheadquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad,India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitterat @ViatrisInc, LinkedIn and YouTube.Forward-Looking Statements: BioconThis press release may include statements of future expectations and other forward-looking statementsbased on management’s current expectations and beliefs concerning future developments and theirpotential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involveknown or unknown risks and uncertainties that could cause actual results, performance or events to differmaterially from those expressed or implied in such statements. Important factors that could cause actualresults to differ materially from our expectations include, amongst other: general economic and businessconditions in India and overseas, our ability to successfully implement our strategy, our research anddevelopment efforts, our growth and expansion plans and technological changes, changes in the value ofthe Rupee and other currency changes, changes in the Indian and international interest rates, change inlaws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries,increasing competition and the conditions of the Indian and global biotechnology and pharmaceuticalsindustries, changes in political conditions in India and changes in the foreign exchange control regulationsin India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation toupdate any particular forward-looking statement contained in this release.Forward-Looking Statements: ViatrisThis press release includes statements that constitute “forward-looking statements.” These statementsare made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.Such forward looking statements may include statements Viatris Inc. and Biocon Biologics Ltd. are proudto confirm that Insulin Glargine (insulin glargine-yfgn) injection will be offered through the WalgreensPrescription Savings Club, saving members up to 80 percent off the cash price of comparable long-actinginsulins purchased at Walgreens; Viatris and Biocon Biologics together are committed to ensuring that theinterchangeable biosimilar insulin glargine can reach as many patients as possible regardless of financialcircumstances, insurance or channel; and the collaboration with Walgreens underscores our efforts toimprove outcomes and access for patients by meeting the needs of cash-paying patients and partneringwith key stakeholders across the country to lower out-of-pocket costs for insulin users. Because forwardlooking statements inherently involve risks and uncertainties, actual future results may differ materiallyfrom those expressed or implied by such statements. Factors that could cause or contribute to suchdifferences include, but are not limited to: the potential impact of public health outbreaks, epidemics andpandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; theintegration of Mylan N.V. and Pfizer Inc.’s Upjohn business (the “Upjohn Business”), which combined toform Viatris (the “Combination”) and the implementation of our global restructuring initiatives beingmore difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieveexpected benefits, synergies and operating efficiencies in connection with the Combination or itsrestructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare andpharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and3
abroad; any regulatory, legal or other impediments to Viatris’ ability to bring new products to market,including but not limited to “at-risk” launches; Viatris’ or its partners’ ability to develop, manufacture andcommercialize products; the scope, timing and outcome of any ongoing legal proceedings and the impactof any such proceedings; any significant breach of data security or data privacy or disruptions to ourinformation technology systems; risks associated with international operations, including our operationsin China; the ability to protect intellectual property and preserve intellectual property rights; changes inthird-party relationships; the effect of any changes in Viatris’ or its partners’ customer and supplierrelationships and customer purchasing patterns; the impacts of competition; changes in the economicand financial conditions of Viatris or its partners; uncertainties and matters beyond the control ofmanagement; and the other risks Viatris’ filings with the Securities and Exchange Commission. Viatrisroutinely uses its website as a means of disclosing material information to the public in a broad, nonexclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Viatris undertakes noobligation to update these statements for revisions or changes after the date of this release other than asrequired by law.Contacts:BIOCON BIOLOGICSVIATRISMEDIASeema AhujaSr. VP & Global Head of Communications & CorporateBrandBiocon Group & Biocon Biologics 91 80 2808 2222 91 99723 [email protected] MallHead, Investor RelationsBiocon Biologics91 998 777 [email protected] Mauer a[email protected] Szablewski [email protected]
Walgreens Prescription Savings Club, saving members up to 80 percent off the cash price of comparable long-acting insulins purchased at Walgreens. This decision by Walgreens follows the launch of Insulin Glargine (insulin glargine-yfgn) announced on November 16. B
